



**Michael Pastier**  
Senior Vice President, Chief Financial Officer  
Mount Sinai Hospital  
150 E 42<sup>nd</sup> Street, 5<sup>th</sup> Floor  
New York, NY 10017  
Tel (212) 731-3149  
Fax (212) 731-3042

February 9, 2017

Dear Manufacturers:

I am writing on behalf of The Mount Sinai Comprehensive Hemophilia Treatment Center (340B ID#HM7439) to inform manufacturers that the Mount Sinai Comprehensive Hemophilia Treatment Center recently underwent an audit by the Health and Human Resources (HRSA) of The Mount Sinai Comprehensive Hemophilia Treatment Center's compliance with 340b Drug Pricing Program (340b Program) requirements.

As background, The Mount Sinai Comprehensive Hemophilia Treatment Center qualified for the 340b Program as comprehensive treatment center in New York and has participated in the 340b Program since April 1, 1995.

Through the audit process, The Mount Sinai Comprehensive Hemophilia Treatment Center was found to have a finding from HRSA stated as follows: "Mount Sinai did not have adequate controls to prevent duplicate discounts which may have resulted in duplicate discounts as prohibited by 42 USC 256b(a)(5)(A)".

The State Medicaid Agency has confirmed no duplicate discounts occurred. If manufacturers have not received notification from The Mount Sinai Comprehensive Hemophilia Treatment Center and believe repayment may be owed for the audit finding described in this letter, or if you have any questions or comments regarding the audit finding described in this letter please contact Frank Cino, Chief Risk and Compliance Officer at (646) 605-7101 150 E. 42<sup>nd</sup> Street. New York, NY 10017.

Sincerely,

Michael Pastier